RUKOBIA Drug Patent Profile

When do Rukobia patents expire, and what generic alternatives are available?

Rukobia is a drug marketed by Viiv Hlthcare and is included in one NDA. There are two patents protecting this drug.

This drug has thirty-nine patent family members in thirty countries.

The generic ingredient in RUKOBIA is fostemsavir tromethamine. One supplier is listed for this compound. Additional details are available on the fostemsavir tromethamine profile page.

DrugPatentWatch^® Generic Entry Outlook for Rukobia

Rukobia was eligible for patent challenges on July 2, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 13, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for RUKOBIA

International Patents:	39
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	49
Clinical Trials:	2
Patent Applications:	189
Drug Prices:	Drug price information for RUKOBIA
What excipients (inactive ingredients) are in RUKOBIA?	RUKOBIA excipients list
DailyMed Link:	RUKOBIA at DailyMed

See drug prices for RUKOBIA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for RUKOBIA

NDA:

212950

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RUKOBIA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Centre hospitalier de l'Universit de Montral (CHUM)	PHASE2
BC Women's Hospital & Health Centre	PHASE2
McGill University Health Centre/Research Institute of the McGill University Health Centre	PHASE2

See all RUKOBIA clinical trials

US Patents and Regulatory Information for RUKOBIA

RUKOBIA is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	RUKOBIA	fostemsavir tromethamine	TABLET, EXTENDED RELEASE;ORAL	212950-001	Jul 2, 2020		RX	Yes	Yes				Y
Viiv Hlthcare	RUKOBIA	fostemsavir tromethamine	TABLET, EXTENDED RELEASE;ORAL	212950-001	Jul 2, 2020		RX	Yes	Yes			Y

Expired US Patents for RUKOBIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	RUKOBIA	fostemsavir tromethamine	TABLET, EXTENDED RELEASE;ORAL	212950-001	Jul 2, 2020

International Patents for RUKOBIA

When does loss-of-exclusivity occur for RUKOBIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Israel

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RUKOBIA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	048039	PROFARMACOS DE PIPERAZINA Y AGENTES ANTIVIRALES DE PIPERIDINA SUSTITUIDOS
Austria	E384728
Australia	2005223736	Prodrugs of piperazine and substituted piperidine antiviral agents
Brazil	PI0508876	pró medicamentos de agentes antivirais de piperazina e piperidina substituìda
Canada	2560253	PRODROGUES DE PIPERAZINE ET AGENTS ANTIVIRAUX DE PIPERIDINE SUBSTITUEE (PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS)

RUKOBIA (fostemsavir) Market Dynamics and Financial Trajectory: Uptake Drivers, Pricing, Revenue Path, and Patent-Settled Competitive Risk

Last updated: July 3, 2026

RUKOBIA (fostemsavir, oral selective attachment inhibitor for HIV-1) has a revenue model built around late-line, multi-drug-resistant HIV patients who have no remaining effective options. Sales traction is tied to (1) penetration among heavily treatment-experienced patients, (2) payer acceptance of a high-cost, brand-only regimen, and (3) pipeline and competitor pressure from next-generation attachment inhibitors, capsid integrase/attachment combinations, and functional-switch strategies in resistance-heavy populations.

---

What is RUKOBIA’s revenue trajectory and how does it perform financially?

Short answer: RUKOBIA’s financial trajectory is best characterized as ramp-to-scale in a constrained niche market: revenue rises with access expansion and clinician adoption in heavily treatment-experienced (HTE) populations, then decelerates as the treatable pool saturates. Public financial reporting is limited because the drug is marketed by ViiV Healthcare and typically reported within broader company segments, not separately at the brand level in investor materials.

Revenue drivers shaping quarterly performance

• Patient pool growth: The eligible population is defined by HTE status and treatment limitation or resistance history. That pool grows with diagnosis and referral rates rather than expanding like first-line ART markets.
• Formulary access: Reimbursement outcomes drive net pricing and persistence. High out-of-pocket costs in niche brands commonly require authorization workflows that can slow early uptake.
• Treatment durability: In HIV, adherence and regimen switching patterns influence repeat prescription volume. In resistance-heavy settings, switching friction is often higher, which can stabilize demand.
• Physician channel and guideline positioning: RUKOBIA competes for use in “salvage” care pathways rather than routine first-line prescribing.

Key commercial watch items for investors

• Uptake in US vs. EU access: Different HTA and reimbursement regimes affect time-to-coverage.
• Net price vs list price: Brand HIV drugs often show discounting via rebates and payer contracting.
• Prescription persistence: Real-world persistence in salvage populations determines whether revenue grows linearly or follows a “pool capture then plateau” curve.

---

What market dynamics drive uptake of RUKOBIA in late-line HIV treatment?

Short answer: Uptake depends on clinicians’ willingness to prescribe in HTE settings, plus payer acceptance of a costly regimen for a small but persistent population.

Where RUKOBIA fits in the HIV sequencing landscape

• RUKOBIA is used when patients have limited treatment options due to resistance and prior therapy exposure.
• This positions the drug inside a salvage segment that has more complex access and prior authorization than chronic maintenance in treatment-naïve or lightly experienced patients.

Demand elasticity in a constrained niche

• Low clinical substitutability: For some resistance profiles, attachment inhibition can remain clinically differentiated. That increases demand stability relative to drugs that address broader indications.
• High access friction: Because HTE use is authorization-driven, uptake is sensitive to payer-specific criteria (e.g., documented resistance, prior regimen failure, genotype history).

Competitive substitution pathways

• Within-class: Alternative attachment inhibition strategies can reduce share if they show superior resistance robustness or dosing convenience.
• Across-mechanism salvage: New combinations that incorporate resistance-breaking anchors can pull prescribers away from RUKOBIA for certain genotypes.
• Biosimilar dynamics do not apply: RUKOBIA is a small-molecule brand, so the competitive pressure resembles other branded ART rather than biologics.

---

How is RUKOBIA priced and what matters for net revenue?

Short answer: For niche, high-cost HIV salvage therapies, net revenue is dominated by reimbursement structure, payer contracting, and authorization throughput.

Pricing mechanics that affect financial outcomes

• List price vs net price: Rebates and payer-specific discounts determine actual realized revenue. In salvage markets, contracting can be stricter because budgets are harder to justify for low-volume prescribers.
• Prior authorization and step therapy: These can slow initial uptake and can depress early-quarter prescriptions.
• Patient assistance: Manufacturer copay support can reduce patient drop-off, but does not replace payer coverage.

What to track for investor-grade signals

• Declining authorization friction: Faster approvals increase conversion of eligible patients into treated patients.
• Payer expansion by geography: EU market entry and US formulary inclusion timelines drive step-function revenue changes.

---

What patents protect RUKOBIA, and when do key exclusivity events occur?

Short answer: A full, decision-grade view of RUKOBIA’s patent estate requires Orange Book-style mapping to US marketed product(s), including any formulation, polymorph, manufacturing, and method-of-use claims. That mapping must be sourced from listed patent numbers and expiration dates. Without a provided patent table or cited patent listings for RUKOBIA, a complete exclusivity timeline cannot be generated without risking incorrect dates.

What is the Orange Book status of RUKOBIA?

Short answer: Orange Book status is determined by the specific branded NDA listing and associated listed patents. A complete status review requires the actual FDA Orange Book record for fostemsavir and its specific dosage form(s). Without the record details, producing a correct listing of patent numbers, expiration dates, and exclusivity periods is not possible.

---

How strong is the patent estate for fostemsavir, and what formulation or method-of-use risks exist?

Short answer: Patent strength for fostemsavir depends on claim coverage across the marketed drug substance and drug product, including:

• crystal form or polymorph IP (if any),
• formulation and stability,
• manufacturing process,
• any method-of-use restrictions tied to the attachment inhibitor’s clinical use.

A strength score and generic-risk assessment require the underlying claim set with jurisdiction-specific expiration dates and any litigation or post-approval amendments. That material is not available in the prompt.

---

What generic entry risks exist for RUKOBIA (Paragraph IV and settlement likelihood)?

Short answer: Generic entry risk depends on (1) listed patent lifetimes, (2) whether there are active Paragraph IV challenges, and (3) whether any settlements constrain launch timing. That determination requires docketed litigation and/or FDA ANDA challenge records specific to RUKOBIA fostemsavir. Those inputs are not present.

---

What litigation or regulatory events affect RUKOBIA’s commercial outlook?

Short answer: Litigation impacts revenue by shifting launch dates for authorized generics or by changing time-to-market for competitors. A correct view needs identified cases and settlement structures. Those details are not included.

---

How does RUKOBIA compare commercially to other late-line HIV drugs?

Short answer: In salvage HIV, revenue typically tracks a curve tied to (1) differentiation versus resistance profiles and (2) payer and provider adoption. RUKOBIA is structurally less exposed to first-line commoditization than broader ART classes because its usage is concentrated in HTE salvage.

Where competition tends to matter most

• HTE referral center prescribing: High-volume HIV treatment centers influence early uptake.
• Resistance-genotype fit: Drugs that retain activity across more resistance patterns can gain share even inside salvage lines.
• Regimen simplicity: Dosing convenience affects switching and persistence.

---

What is the competitive landscape for oral HIV salvage attachment inhibition?

Short answer: Competition in late-line HIV centers on drug classes that maintain efficacy in resistant populations and show payer-favorable access. RUKOBIA competes for salvage slots; it does not compete head-to-head with first-line regimens at scale.

Competitor dynamics to model financially

• Therapeutic substitution: If competitors offer better resistance coverage, RUKOBIA’s incremental patient capture slows.
• Access displacement: Even if clinical outcomes are comparable, formulary position can dictate share.
• New entrants: Next-generation agents that enter earlier in salvage lines can shift demand away from existing brands.

---

Key Takeaways

• RUKOBIA’s financial trajectory is driven by salvage penetration in HTE HIV patients rather than first-line market expansion.
• Revenue growth is most sensitive to payer access, authorization friction, and physician adoption in resistance-heavy referral pathways.
• Demand is relatively stable once covered in salvage care because regimen switching in HTE can be difficult, but the addressable pool can plateau.
• A reliable patent-exclusivity and generic-risk timeline requires exact listed patent numbers and expiration dates from FDA records and any associated litigation dockets. Those data were not provided, so exclusivity timing and launch-risk conclusions cannot be stated without error.

---

FAQs

1. What patient segments are most likely to start RUKOBIA?
2. How does prior authorization affect real-world RUKOBIA prescription volume?
3. Does RUKOBIA’s demand behave more like a chronic therapy or a one-time rescue switch?
4. What payer formulary dynamics typically determine net pricing for niche HIV salvage brands?
5. How should investors model RUKOBIA’s plateau risk as the HTE pool matures?

---

References

1. (No sources cited because no FDA Orange Book, company financial filings, pricing datasets, or litigation/patent listings were provided in the prompt.)

DrugChatter Q&A for RUKOBIA

Rukobia prescribing information?
Rukobia mechanism of action?